Rosiglitazone activation of PPARγ-dependent signaling is neuroprotective in mutant huntingtin expressing cells (Q38835914)

6 September 2017

title

Rosiglitazone activation of PPARγ-dependent signaling is neuroprotective in mutant huntingtin expressing cells (English)

1 reference

6 September 2017

1 reference

Ming-Chang Chiang

1

1 reference

6 September 2017

Yi-Chuan Cheng

2

1 reference

6 September 2017

Christopher J Nicol

3

1 reference

6 September 2017

Kuan-Hung Lin

4

1 reference

6 September 2017

Chia-Hui Yen

5

1 reference

6 September 2017

Shiang-Jiuun Chen

6

1 reference

6 September 2017

Rong-Nan Huang

7

1 reference

6 September 2017

language of work or name

English

0 references

publication date

8 September 2015

1 reference

Experimental Cell Research

6 September 2017

published in

1 reference

6 September 2017

volume

338

1 reference

6 September 2017

issue

2

1 reference

6 September 2017

page(s)

183-193

1 reference

Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Huntington's disease. Pathogenesis and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Recent advances in understanding the pathogenesis of Huntington's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Protein aggregates in Huntington's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Identities of sequestered proteins in aggregates from cells with induced polyglutamine expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

The A2A adenosine receptor rescues the urea cycle deficiency of Huntington's disease by enhancing the activity of the ubiquitin-proteasome system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Indirect inhibition of 26S proteasome activity in a cellular model of Huntington's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Polyglutamine aggregates stimulate ER stress signals and caspase-12 activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Obesity and the regulation of energy balance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

PPAR gamma, 10 years later

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

The many faces of PPARgamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

PPARgamma as a therapeutic target in central nervous system diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

PPARgamma agonists as new therapeutic agents for the treatment of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Modulation of energy deficiency in Huntington's disease via activation of the peroxisome proliferator-activated receptor gamma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

cAMP-response element-binding protein contributes to suppression of the A2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

β-adrenoceptor pathway enhances mitochondrial function in human neural stem cells via rotary cell culture system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Rosiglitazone promotes neurite outgrowth and mitochondrial function in N2A cells via PPARgamma pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Dysregulation of C/EBPalpha by mutant Huntingtin causes the urea cycle deficiency in Huntington's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Systematic uncovering of multiple pathways underlying the pathology of Huntington disease by an acid-cleavable isotope-coded affinity tag approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

PPARγ regulates the mitochondrial dysfunction in human neural stem cells with tumor necrosis factor alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

The neuroprotective role of metformin in advanced glycation end product treated human neural stem cells is AMPK-dependent.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Changes in BiP availability reveal hypersensitivity to acute endoplasmic reticulum stress in cells expressing mutant huntingtin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Examining the safety of PPAR agonists - current trends and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Peroxisome Proliferator-Activated Receptor-gamma in Amyotrophic Lateral Sclerosis and Huntington's Disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: possible role of peroxisome proliferator activated receptor-Upsilon (PPARUpsilon) in Huntington's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Protective effect of pioglitazone, a PPARγ ligand, in a 3 nitropropionic acid model of Huntington's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Metabolic state determines sensitivity to cellular stress in Huntington disease: normalization by activation of PPARγ.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

PGC-1α at the intersection of bioenergetics regulation and neuron function: from Huntington's disease to Parkinson's disease and beyond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Proteasomes: machines for all reasons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Proteostasis and neurodegeneration: the roles of proteasomal degradation and autophagy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Illuminating the ubiquitin/proteasome system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Impairment of the ubiquitin-proteasome system by protein aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

The ubiquitin-proteasome pathway in health and disease of the nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Regulation of proteasome activity in health and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Global changes to the ubiquitin system in Huntington's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Is the ubiquitin-proteasome system impaired in Huntington's disease?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Ubiquitin ligase Hrd1 enhances the degradation and suppresses the toxicity of polyglutamine-expanded huntingtin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Gene expression profiling of potential PPARgamma target genes in mouse aorta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Hsp70 chaperones: cellular functions and molecular mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

To be, or not to be--molecular chaperones in protein degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Modulation of polyglutamine inclusion formation by the Hsp70 chaperone machine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Roles of Hsp104 and trehalose in solubilisation of mutant huntingtin in heat shocked Saccharomyces cerevisiae cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Active HSF1 significantly suppresses polyglutamine aggregate formation in cellular and mouse models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

ER stress and neurodegenerative diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Rrs1 is involved in endoplasmic reticulum stress response in Huntington disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Inhibition of endoplasmic reticulum stress counteracts neuronal cell death and protein aggregation caused by N-terminal mutant huntingtin proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Coupling endoplasmic reticulum stress to the cell death program. An Apaf-1-independent intrinsic pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Intranuclear huntingtin increases the expression of caspase-1 and induces apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Inhibitors of metabolism rescue cell death in Huntington's disease models.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

Neuropathological classification of Huntington's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2015.09.005

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YEXCR.2015.09.005

1 reference

6 September 2017

1 reference